 <h1>Ivabradine Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of ivabradine include:</b> bradycardia. <b>Other side effects include:</b> atrial fibrillation.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ivabradine: oral solution, oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ivabradine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking ivabradine:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>chest pain or discomfort</li>
<li>fast or irregular heartbeat</li>
<li>headache</li>
<li>lightheadedness, dizziness, or fainting</li>
<li>nervousness</li>
<li>pounding in the ears</li>
<li>slow or irregular heartbeat</li>
<li>unusual tiredness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Confusion</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>hives or welts, itching, or skin rash</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>sweating</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ivabradine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Seeing flashes of light</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Double vision</li>
<li>feeling of constant movement of self or surroundings</li>
<li>flushing or redness of the skin</li>
<li>seeing double</li>
<li>sensation of spinning</li>
<li>trouble seeing</li>
<li>unusually warm skin</li>
</ul><p>
<!-- end oral solution, oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ivabradine: oral liquid, oral tablet</i></p><h3>General</h3><p>The most common side effects were cardiac failure, phosphene-like events, and bradycardia.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Cardiac failure (21.7%), bradycardia (up to 10%)</p>
<p><b>Common</b> (1% to 10%): Hypertension, blood pressure increased, atrial fibrillation, ventricular extrasystoles, atrioventricular block first degree, unstable angina, angina pectoris aggravated, myocardial ischemia, blood pressure inadequately controlled, sinus tachycardia, supraventricular extrasystoles, atrial flutter, ventricular tachycardia, bradycardia symptomatic, bradycardia asymptomatic, angina pectoris, acute myocardial infarction, myocardial infarction, hypotension, sudden cardiac death</p>
<p><b>Uncommon</b> (0.1% to 1%): Palpitations, sinus arrhythmia, ECG prolonged QT interval</p>
<p><b>Very rare</b> (less than 0.01%): Atrioventricular block second degree, atrioventricular block third degree, sick sinus syndrome</p>
<p><b>Postmarketing reports</b>: Torsade de pointes, ventricular fibrillation<sup>[Ref]</sup></p><h3>Ocular</h3><p>Phosphenes generally occur within the first 2 months of treatment and may occur repeatedly afterward.  They were generally reported as mild to moderate in intensity and led to discontinuation in less than 1% of patients.  Most cases resolved during or after treatment.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Phosphene-like events (14.5%)</p>
<p><b>Common</b> (1% to 10%): Phosphenes, visual brightness, blurred vision</p>
<p><b>Uncommon</b> (0.1% to 1%): Diplopia, visual impairment<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pneumonia, bronchitis acute, bronchitis, nasopharyngitis, upper respiratory tract infection, respiratory tract infection, influenza, cough, chronic obstructive pulmonary disease</p>
<p><b>Uncommon</b> (0.1% to 1%): Dyspnea<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Diabetes mellitus inadequately controlled, diabetes mellitus, hypercholesterolemia, hypokalemia, hyperuricemia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness, ischemic stroke</p>
<p><b>Uncommon</b> (0.1% to 1%): Syncope<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Sudden death, fall</p>
<p><b>Uncommon</b> (0.1% to 1%): Vertigo, asthenia, fatigue</p>
<p><b>Rare</b> (less than 0.1%): Malaise<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea, gastritis</p>
<p><b>Uncommon</b> (0.1% to 1%): Nausea, constipation, abdominal pain<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Blood creatinine increased, anemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Eosinophilia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Renal failure<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Transaminases increased<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Angioedema, rash</p>
<p><b>Rare</b> (less than 0.1%): Erythema, pruritus, urticaria<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Muscle cramps<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Corlanor (ivabradine)." Amgen USA, Thousand Oaks, CA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about ivabradine</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>4 Reviews</li>
<li>Drug class: miscellaneous cardiovascular agents</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ivabradine &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Corlanor</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Heart Failure</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ivabradine: oral liquid, oral tablet</i></p><h3>General</h3><p>The most common side effects were cardiac failure, phosphene-like events, and bradycardia.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Cardiac failure (21.7%), bradycardia (up to 10%)</p><p><b>Common</b> (1% to 10%): Hypertension, blood pressure increased, atrial fibrillation, ventricular extrasystoles, atrioventricular block first degree, unstable angina, angina pectoris aggravated, myocardial ischemia, blood pressure inadequately controlled, sinus tachycardia, supraventricular extrasystoles, atrial flutter, ventricular tachycardia, bradycardia symptomatic, bradycardia asymptomatic, angina pectoris, acute myocardial infarction, myocardial infarction, hypotension, sudden cardiac death</p><p><b>Uncommon</b> (0.1% to 1%): Palpitations, sinus arrhythmia, ECG prolonged QT interval</p><p><b>Very rare</b> (less than 0.01%): Atrioventricular block second degree, atrioventricular block third degree, sick sinus syndrome</p><p><b>Postmarketing reports</b>: Torsade de pointes, ventricular fibrillation<sup>[Ref]</sup></p><h3>Ocular</h3><p>Phosphenes generally occur within the first 2 months of treatment and may occur repeatedly afterward.  They were generally reported as mild to moderate in intensity and led to discontinuation in less than 1% of patients.  Most cases resolved during or after treatment.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Phosphene-like events (14.5%)</p><p><b>Common</b> (1% to 10%): Phosphenes, visual brightness, blurred vision</p><p><b>Uncommon</b> (0.1% to 1%): Diplopia, visual impairment<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pneumonia, bronchitis acute, bronchitis, nasopharyngitis, upper respiratory tract infection, respiratory tract infection, influenza, cough, chronic obstructive pulmonary disease</p><p><b>Uncommon</b> (0.1% to 1%): Dyspnea<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Diabetes mellitus inadequately controlled, diabetes mellitus, hypercholesterolemia, hypokalemia, hyperuricemia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness, ischemic stroke</p><p><b>Uncommon</b> (0.1% to 1%): Syncope<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Sudden death, fall</p><p><b>Uncommon</b> (0.1% to 1%): Vertigo, asthenia, fatigue</p><p><b>Rare</b> (less than 0.1%): Malaise<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea, gastritis</p><p><b>Uncommon</b> (0.1% to 1%): Nausea, constipation, abdominal pain<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Blood creatinine increased, anemia</p><p><b>Uncommon</b> (0.1% to 1%): Eosinophilia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Renal failure<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Transaminases increased<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Angioedema, rash</p><p><b>Rare</b> (less than 0.1%): Erythema, pruritus, urticaria<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Muscle cramps<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Corlanor (ivabradine)." Amgen USA, Thousand Oaks, CA. </p><h2>More about ivabradine</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>4 Reviews</li>
<li>Drug class: miscellaneous cardiovascular agents</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ivabradine &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Heart Failure</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>